vs
GEE Group Inc.（JOB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是GEE Group Inc.的1.5倍（$30.3M vs $20.5M），GEE Group Inc.净利率更高（-0.7% vs -221.3%，领先220.6%），REGENXBIO Inc.同比增速更快（43.0% vs -21.2%），GEE Group Inc.自由现金流更多（$-1.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -10.5%）
GEE Group Inc.是总部位于美国的专业人力资源解决方案提供商，提供临时用工、合同工安置及永久岗位招聘服务，覆盖信息技术、医疗、财会、法律、轻工制造等核心领域，服务北美市场各规模的客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
JOB vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.5M
营收增速更快
RGNX
高出64.2%
-21.2%
净利率更高
JOB
高出220.6%
-221.3%
自由现金流更多
JOB
多$51.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-10.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.5M | $30.3M |
| 净利润 | $-150.0K | $-67.1M |
| 毛利率 | 36.1% | — |
| 营业利润率 | -2.0% | -190.0% |
| 净利率 | -0.7% | -221.3% |
| 营收同比 | -21.2% | 43.0% |
| 净利润同比 | 78.3% | -31.2% |
| 每股收益（稀释后） | $0.00 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JOBRGNX
| Q4 25 | $20.5M | $30.3M | ||
| Q3 25 | $23.5M | $29.7M | ||
| Q2 25 | $24.5M | $21.4M | ||
| Q1 25 | $24.5M | $89.0M | ||
| Q4 24 | $24.0M | $21.2M | ||
| Q3 24 | $23.7M | $24.2M | ||
| Q2 24 | $27.0M | $22.3M | ||
| Q1 24 | $25.6M | $15.6M |
净利润JOBRGNX
| Q4 25 | $-150.0K | $-67.1M | ||
| Q3 25 | $-513.0K | $-61.9M | ||
| Q2 25 | $-423.0K | $-70.9M | ||
| Q1 25 | $-33.1M | $6.1M | ||
| Q4 24 | $-692.0K | $-51.2M | ||
| Q3 24 | $-2.3M | $-59.6M | ||
| Q2 24 | $-19.3M | $-53.0M | ||
| Q1 24 | $-1.0M | $-63.3M |
毛利率JOBRGNX
| Q4 25 | 36.1% | — | ||
| Q3 25 | 35.8% | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | 34.1% | — | ||
| Q4 24 | 33.0% | 70.2% | ||
| Q3 24 | 37.1% | 48.8% | ||
| Q2 24 | 34.1% | 52.5% | ||
| Q1 24 | 32.8% | 72.6% |
营业利润率JOBRGNX
| Q4 25 | -2.0% | -190.0% | ||
| Q3 25 | -3.3% | -176.3% | ||
| Q2 25 | -2.2% | -296.3% | ||
| Q1 25 | -94.8% | 13.6% | ||
| Q4 24 | -3.2% | -242.1% | ||
| Q3 24 | -5.8% | -256.6% | ||
| Q2 24 | -76.6% | -251.3% | ||
| Q1 24 | -7.6% | -408.8% |
净利率JOBRGNX
| Q4 25 | -0.7% | -221.3% | ||
| Q3 25 | -2.2% | -208.3% | ||
| Q2 25 | -1.7% | -331.8% | ||
| Q1 25 | -135.2% | 6.8% | ||
| Q4 24 | -2.9% | -241.3% | ||
| Q3 24 | -9.5% | -246.3% | ||
| Q2 24 | -71.3% | -237.7% | ||
| Q1 24 | -3.9% | -405.4% |
每股收益（稀释后）JOBRGNX
| Q4 25 | $0.00 | $-1.30 | ||
| Q3 25 | $-0.01 | $-1.20 | ||
| Q2 25 | $0.00 | $-1.38 | ||
| Q1 25 | $-0.30 | $0.12 | ||
| Q4 24 | $-0.01 | $-0.99 | ||
| Q3 24 | $-0.02 | $-1.17 | ||
| Q2 24 | $-0.18 | $-1.05 | ||
| Q1 24 | $-0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $50.0M | $102.7M |
| 总资产 | $58.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JOBRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益JOBRGNX
| Q4 25 | $50.0M | $102.7M | ||
| Q3 25 | $50.0M | $161.5M | ||
| Q2 25 | $50.4M | $213.7M | ||
| Q1 25 | $50.6M | $274.2M | ||
| Q4 24 | $83.6M | $259.7M | ||
| Q3 24 | $84.2M | $301.4M | ||
| Q2 24 | $86.3M | $348.3M | ||
| Q1 24 | $105.5M | $390.7M |
总资产JOBRGNX
| Q4 25 | $58.9M | $453.0M | ||
| Q3 25 | $60.0M | $525.2M | ||
| Q2 25 | $60.6M | $581.0M | ||
| Q1 25 | $61.8M | $490.9M | ||
| Q4 24 | $92.8M | $466.0M | ||
| Q3 24 | $95.9M | $519.1M | ||
| Q2 24 | $96.9M | $569.4M | ||
| Q1 24 | $117.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | -5.8% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流JOBRGNX
| Q4 25 | $-1.2M | $-52.3M | ||
| Q3 25 | $2.4M | $-56.0M | ||
| Q2 25 | $-743.0K | $-49.3M | ||
| Q1 25 | $-24.0K | $33.6M | ||
| Q4 24 | $-1.1M | $-31.6M | ||
| Q3 24 | $1.3M | $-40.5M | ||
| Q2 24 | $-1.5M | $-45.5M | ||
| Q1 24 | $1.3M | $-55.5M |
自由现金流JOBRGNX
| Q4 25 | $-1.2M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $-755.0K | $-49.7M | ||
| Q1 25 | $-27.0K | $32.6M | ||
| Q4 24 | $-1.1M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | $-1.6M | $-46.0M | ||
| Q1 24 | $1.3M | $-56.0M |
自由现金流率JOBRGNX
| Q4 25 | -5.8% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | -3.1% | -232.8% | ||
| Q1 25 | -0.1% | 36.6% | ||
| Q4 24 | -4.7% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | -5.8% | -206.2% | ||
| Q1 24 | 5.2% | -358.5% |
资本支出强度JOBRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率JOBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JOB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
